Nabi Biopharmaceuticals Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Aug 6 Calls Today's Calls

Call Details Nabi Biopharmaceuticals Earnings Conference Call (Q2 2009) Thu, Aug 6, 2009, 4:30 pm Eastern Listen to the archived event audio About Nabi Biopharmaceuticals (NasdaqGM:NABI) Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company’s products in development includes Nicotine Conjugate Vaccine, a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse; and Pentavalent S.aureus Vaccine, a pentavalent vaccine designed to prevent S.aureus infections, including those infections caused by antibiotic-resistant strains of S.aureus. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland. The company was founded in 1967 and is headquartered in Rockville, Maryland. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials